

Supplementary Table S1: Clinical characteristics of HPV16 positive CaCx patients (n=44) included in the study

| Characteristics | Number | percentage (%) |
|-------------------------------------|---------------|-----------------------|
| FIGO stage | | |
| Early (\leq IIA) | 9 | 20.45454545 |
| Late (\geq IIB) | 34 | 77.27272727 |
| Not known | 1 | 2.272727273 |
| Lymph node involvement | | |
| Involved (pN+) | 19 | 43.18181818 |
| Not involved (pN-) | 24 | 54.54545455 |
| Not known | 1 | 2.272727273 |
| Survival status | | |
| Survivors | 25 | 56.81818182 |
| Deceased | 10 | 22.72727273 |
| LTFU | 8 | 18.18181818 |
| Not known | 1 | 2.272727273 |
| Parametrium Node involvement | | |
| Involved | 30 | 68.18181818 |
| Not involved | 11 | 25 |
| Not known | 3 | 6.818181818 |